These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 18457819

  • 1. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L.
    Sasaki A, Kawarabayashi T, Murakami T, Matsubara E, Ikeda M, Hagiwara H, Westaway D, George-Hyslop PS, Shoji M, Nakazato Y.
    Brain Res; 2008 Jun 12; 1214():159-68. PubMed ID: 18457819
    [Abstract] [Full Text] [Related]

  • 2. Partial reduction of microglia does not affect tau pathology in aged mice.
    Bennett RE, Bryant A, Hu M, Robbins AB, Hopp SC, Hyman BT.
    J Neuroinflammation; 2018 Nov 09; 15(1):311. PubMed ID: 30413160
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
    Köhler C, Bista P, Götz J, Schröder H.
    Brain Res; 2010 Aug 06; 1347():111-24. PubMed ID: 20513372
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
    Ishikawa A, Tokunaga M, Maeda J, Minamihisamatsu T, Shimojo M, Takuwa H, Ono M, Ni R, Hirano S, Kuwabara S, Ji B, Zhang MR, Aoki I, Suhara T, Higuchi M, Sahara N.
    J Alzheimers Dis; 2018 Aug 06; 61(3):1037-1052. PubMed ID: 29332041
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
    Javidnia M, Hebron ML, Xin Y, Kinney NG, Moussa CE.
    J Alzheimers Dis; 2017 Aug 06; 60(2):461-481. PubMed ID: 28869476
    [Abstract] [Full Text] [Related]

  • 10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.
    Exp Neurol; 2008 Jul 06; 212(1):71-84. PubMed ID: 18490011
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Age-dependent effects of microglial inhibition in vivo on Alzheimer's disease neuropathology using bioactive-conjugated iron oxide nanoparticles.
    Glat M, Skaat H, Menkes-Caspi N, Margel S, Stern EA.
    J Nanobiotechnology; 2013 Sep 23; 11():32. PubMed ID: 24059692
    [Abstract] [Full Text] [Related]

  • 14. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
    Ren Y, Lin WL, Sanchez L, Ceballos C, Polydoro M, Spires-Jones TL, Hyman BT, Dickson DW, Sahara N.
    J Alzheimers Dis; 2014 Sep 23; 38(3):589-600. PubMed ID: 24028867
    [Abstract] [Full Text] [Related]

  • 15. Soluble phospho-tau from Alzheimer's disease hippocampus drives microglial degeneration.
    Sanchez-Mejias E, Navarro V, Jimenez S, Sanchez-Mico M, Sanchez-Varo R, Nuñez-Diaz C, Trujillo-Estrada L, Davila JC, Vizuete M, Gutierrez A, Vitorica J.
    Acta Neuropathol; 2016 Dec 23; 132(6):897-916. PubMed ID: 27743026
    [Abstract] [Full Text] [Related]

  • 16. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.
    Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O, Novak M.
    J Neuroinflammation; 2010 Oct 12; 7():64. PubMed ID: 20937161
    [Abstract] [Full Text] [Related]

  • 17. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
    van Olst L, Verhaege D, Franssen M, Kamermans A, Roucourt B, Carmans S, Ytebrouck E, van der Pol SMA, Wever D, Popovic M, Vandenbroucke RE, Sobrino T, Schouten M, de Vries HE.
    Neurobiol Aging; 2020 May 12; 89():89-98. PubMed ID: 32008854
    [Abstract] [Full Text] [Related]

  • 18. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S, Iba M, Zhang B, Raible KM, Lee VM, Trojanowski JQ.
    Acta Neuropathol; 2015 Feb 12; 129(2):221-37. PubMed ID: 25534024
    [Abstract] [Full Text] [Related]

  • 19. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
    Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M.
    Neuron; 2013 Sep 18; 79(6):1094-108. PubMed ID: 24050400
    [Abstract] [Full Text] [Related]

  • 20. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
    Sahara N, Vega IE, Ishizawa T, Lewis J, McGowan E, Hutton M, Dickson D, Yen SH.
    J Neurochem; 2004 Aug 18; 90(4):829-38. PubMed ID: 15287888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.